Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

LONG-TERM DOSING WITH THE CAPSID ASSEMBLY MODULATOR ALG-000184 RESULTS IN MULTI-LOG REDUCTIONS OF DNA, RNA, HBsAg, HBeAg AND HBcrAg IN UNTREATED HBeAg POSITIVE CHRONIC HEPATITIS B SUBJECTS

Friday, November 10, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the positive results from long-term dosing of the capsid assembly modulator ALG-000184, which led to multi-log reductions in DNA, RNA, HBsAg, HBeAg, and HBcrAg in untreated HBeAg positive chronic hepatitis B patients. These findings suggest a promising therapeutic approach for managing chronic HBV infection.
Price reaction · baseline $19.415 (2023-11-10T14:36:00.000Z) · hit during market hours · 2 other ALGS headline(s) in the window, move may be shared
day 0 close
-10%
day 1 · peak
-22.7%
day 3
-17.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Long-term dosing shows significant reductions in multiple viral markers.
  • Effective in untreated HBeAg positive chronic hepatitis B subjects.
  • Potential for improved patient outcomes in chronic HBV infection.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-000184?

ALG-000184 is a capsid assembly modulator aimed at treating chronic hepatitis B.

What were the results of the long-term dosing?

Long-term dosing resulted in multi-log reductions of DNA, RNA, and various viral markers.

Who were the subjects in the study?

The study involved untreated HBeAg positive chronic hepatitis B subjects.

What implications do these results have?

The results suggest potential improvements in managing chronic HBV infection.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-000184 chronic hepatitis B HBV HBeAg viral markers
Last updated: Nov 10, 2023

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →